As of January 2021, shown below are the marine-derived compounds which have either been approved, or are in Phase III, II or I of drug development, and are part of the global marine pharmaceutical clinical pipeline. For a comprehensive review prior to 2011 see A.M.S. Mayer, K.B. Glaser, C. Cuevas, R.S. Jacobs, W. Kem, R.D. Little, J. M McIntosh, D.J. Newman, B.C. Potts and D. E. Shuster, Trends in Pharmacological Sciences, 31:255-265, 2010  TIPS (PDF Doc). This peer-reviewed publication has been cited 696 times (Google Scholar, December 2020). A Global Marine Pharmaceutical Pipeline powerpoint presentation at the 5th IUPHAR World Conference on the Pharmacology of Natural Products, Hyderabad, India (http://www.wcpnaturalproducts.org/), December 2019, is available by clicking the link: https://www.youtube.com/watch?v=vSH_q4ab1hQ&t=10s

APPROVED MARINE DRUGS

 
 

PHASE III CLINICAL STATUS

PHASE II CLINICAL STATUS

 
 

PHASE I CLINICAL STATUS

ABBREVIATIONS:

  • ADC: Antibody Drug Conjugate;

  • Ara-A: 9-β-D-arabinofuranosyladenine

  • Ara-C: Cytosine Arabinoside

  • BCMA: B-cell Maturation Antigen

  • CD: Cluster of Differentiation;

  • c-Met: Tyrosine-Protein Kinase Met

  • DMXBA: 3-(2,4-Dimethoxybenzylidene)-Anabaseine

  • EGFR: Epidermal Growth Factor Receptor;

  • ENPP3: Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3

  • FDA: Food and Drug Administration;

  • GPNMB: Glycoprotein nonmetastatic B;

  • LIV-1: Zinc transporter SLC39A6;

  • LRRC15: Leucine rich repeat containing 15

  • MMAE: Monomethylauristatin E;

  • MMAF: Monomethylauristatin F;

  • NaPi2b: Sodium-Dependent Phosphate Transport Protein 2b;

  • PSMA: Prostate-Specific Membrane Antigen;

  • TIM-1: T-cell Immunoglobulin domain 1